We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen to Buy Drug Development Partner Abgenix for $2.2 Billion
Amgen to Buy Drug Development Partner Abgenix for $2.2 Billion
December 15, 2005
Amgen, the world’s largest biotechnology company, will acquire drug development partner Abgenix for $2.2 billion, allowing Amgen to acquire a promising experimental cancer drug that may spell trouble for Bristol-Myers Squibb’s (BMS) and ImClone’s competing drug Erbitux.